Difference between revisions of "Eltrombopag (Promacta)"
Jump to navigation
Jump to search
m |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.<ref name="insert">[http://us.gsk.com/products/assets/us_promacta.pdf Eltrombopag (Promacta) package insert]</ref><ref>[[Media:Eltrombopag.pdf | Eltrombopag (Promacta) package insert (locally hosted backup)]]</ref><ref>[http://www.promacta.com Promacta manufacturer's website]</ref> | Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.<ref name="insert">[http://us.gsk.com/products/assets/us_promacta.pdf Eltrombopag (Promacta) package insert]</ref><ref>[[Media:Eltrombopag.pdf | Eltrombopag (Promacta) package insert (locally hosted backup)]]</ref><ref>[http://www.promacta.com Promacta manufacturer's website]</ref> | ||
| Line 9: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://us.gsk.com/products/assets/us_promacta.pdf | + | *[http://us.gsk.com/products/assets/us_promacta.pdf Eltrombopag (Promacta) package insert]<ref name="insert"></ref> |
| − | |||
*[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *11/20/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129214.htm Initial FDA approval] for treatment of "thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy." | ||
| + | *11/19/2012: FDA approved for treatment of "thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy." | ||
| + | *8/26/2014: FDA approved for "patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy." | ||
| + | |||
| + | ==Also known as== | ||
| + | Revolade, SB-497115-GR. | ||
==References== | ==References== | ||
| Line 20: | Line 25: | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
| + | [[Category:Aplastic anemia medications]] | ||
[[Category:Immune thrombocytopenic purpura (ITP) medications]] | [[Category:Immune thrombocytopenic purpura (ITP) medications]] | ||
Revision as of 05:23, 8 September 2014
General information
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Eltrombopag (Promacta) package insert[1]
- Eltrombopag (Promacta) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/20/2008: Initial FDA approval for treatment of "thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy."
- 11/19/2012: FDA approved for treatment of "thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy."
- 8/26/2014: FDA approved for "patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy."
Also known as
Revolade, SB-497115-GR.